Tirzepatide
Also known as: Mounjaro, Zepbound, LY3298176
At a glance
PeptiGuide dataset · reviewed Aug 2026
What it is
A source-reported GIP/GLP-1 dual-agonist peptide with FDA-approved indications.
Status
FDA Approved
Typical dose
5–15mg
Researched for
Weight loss, diabetes management, metabolic health
Trial progress
- PrePreclinical
- IPhase I
- IIPhase II
- IIIPhase III
- IVPhase IV
- FDAFDA approved
FDA approved - FDA-approved for specific uses with established human evidence
Use the tools
Stay current
Get updates on Tirzepatide
New studies, regulatory decisions and data corrections - delivered when they land.
In plain language
- Single described by the source as a GIP/ dual .
- The source reports FDA-approved indications for type 2 diabetes (adults and pediatric 10+), chronic weight management, and obstructive sleep apnea; Mounjaro and Zepbound are listed aliases.
- Reported administration is a weekly injection, with a community-reported range of 2.5-15 mg weekly.
How it's thought to work
Tirzepatide is described as a dual of GIP and receptors, two gut incretin signals associated with eating. In the source account, GLP-1 activity is linked to glucose-dependent insulin release, lower glucagon, delayed gastric emptying, and appetite reduction. GIP activity is described as potentially augmenting insulin response and energy handling in fat tissue, and the source says dual activity may outperform GLP-1-only activity. It also reports a fatty-acid chain that promotes albumin binding for weekly dosing, while noting that the added role of GIP is not fully resolved.
What the research shows
Where the research stands
The source reports that SURMOUNT-1, published in the New England Journal of Medicine in 2022, involved adults with obesity without diabetes. It describes average body-weight change of 22.5 % with 15 mg over 72 weeks (a 72 week duration) versus 2.4 % with placebo, and says about 9 in 10 participants lost weight. For SURMOUNT-5 (2025), the source reports roughly 20 % weight loss for tirzepatide compared with about 14 % for semaglutide. It further describes HbA1c reductions in the SURPASS diabetes program and says a large cardiovascular outcomes trial supported its safety profile. The source characterizes the cited trials as large, randomized, and peer-reviewed; the listed references should be reviewed for methods and results.
What it shows
✓ Human clinical evidence
FDA-approved for specific uses with established human evidence
△ Limitations
Use only according to approved labeling and qualified medical guidance.
Bottom line: FDA Approved - Type 2 diabetes (adults and pediatric 10+), chronic weight management, obstructive sleep apnea Reported FDA approval: Mounjaro for type 2 diabetes (adults and pediatric 10+); Zepbound for chronic weight management and obstructive sleep apnea.
Typical dosing
CommunityCommunity dataset5–15 mg
weekly (after titration)
The community entry describes increases at 4 week intervals beginning at 2.5 mg, reports 10 mg as effective for weight loss for many people, and notes gastrointestinal effects during titration.
Research dosing
Indication-specificApproved for specific uses - study doses are indication-specific
Timing & administration
Best time to take
Morning, same day each week
Once weekly, same day and time
Food recommendation
With or without food
Why this timing?
The source describes keeping a weekly injection schedule consistent and associates morning timing with establishing a routine and observing tolerability.
Possible side effects
Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Decreased appetite
- Abdominal pain
- Injection site reactions
- Hypoglycemia (with insulin/sulfonylureas)
- Pancreatitis
- Gallbladder problems
- Acute kidney injury
- Thyroid C-cell tumors
Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.
Sources
Frequently asked questions
Sequence
Y-Aib-EGTFTSDYSI-Aib-LDKIAQK(1)AFVQWLIAGGPSSGAPPPS-NH2; C20-diacid-gamma-Glu-2xAEEA linked at Lys20
One open dataset
Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.
Browse the datasetEducational resource, not medical advice. Talk to your clinician before acting on anything here.
Community discussion
Comments are moderated before they appear. Keep it evidence-focused.